This page is designed to include guidelines, consensus statements, overview articles, and current systematic reviews and meta-analyses on therapies for Covid 19. Recent reports from major scholarly publications are included and there are links to data sets, disease trackers, and major clinical trial sites.
News release University of Oxford 6-28-21
Siemieniuk RA, Bartoszko JJ, Diaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231. doi: 10.1136/bmj.n2231.
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
ACTIV-3/TICO LY-CoV555 Study Group March 11, 2021 N Engl J Med 2021; 384:905-914
Weinreich, S. (2020). REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2035002
Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. Published online January 21, 2021. doi:10.1001/jama.2021.0202
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5:S0140-6736(20)32013-4. doi: 10.1016/S0140-6736(20)32013-4. Epub ahead of print. PMID: 33031764; PMCID: PMC7535623.
Mariette X, et al "Effectiveness of tocilizumab in patients hospitalized with COVID-19: A follow-up of the CORIMUNO-TOCI-1 randomized clinical trial" JAMA Intern Med 2021; DOI: 10.1001/jamainternmed.2021.2209.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
Lin WT, Hung SH, Lai CC, et al. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021 Mar 24;96:107602. doi: 10.1016/j.intimp.2021.107602.
Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021 Mar 4. pii: S2213-2600(21)00081-3. doi: 10.1016/S2213-2600(21)00081-3.
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia Ivan O. Rosas, M.D., Norbert Bräu, M.D., Michael Waters, M.D., Ronaldo C. Go, M.D., Bradley D. et al ,
February 25, 2021
DOI: 10.1056/NEJMoa2028700 NEJM
Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
Kamel AM, Monem MSA, Sharaf NA, et al. Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. Rev Med Virol. 2021 Jun 2:e2258. doi: 10.1002/rmv.2258.
Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021 Jul 9. pii: S2213-2600(21)00263-0. doi: 10.1016/S2213-2600(21)00263-0.
Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. Published online July 16, 2021. doi:10.1001/jama.2021.11517